About BetaCure

Hyperinsulinemic hypoglycemia is a potentially lethal disease caused by excessive production of insulin by the beta cells of the pancreatic islets of Langerhans. Lethal hypoglycemia and brain damage is a problem especially in infants born with the disease. The major problem of current therapeutic approaches are the frequently observed severe side effects/morbidity.


In order to significantly reduce the side effects of current therapeutic approaches and to increase quality of life and life expectancy, BetaCure aims to develop an integrated simultaneous imaging/therapeutic (“theranostic”) platform that will allow diagnostic imaging, targeted image guided surgical, photodynamic and radiopeptide therapy to selectively resect or destroy diseased beta cells.


The theranostic platform shall optimize treatment of newborns and infants suffering from congenital hyperinsulinism (CHI) and shall improve the treatment of adult hyperinsulinemic hypoglycemia (AHH) caused by insulin-producing tumours or adult beta cell hyperplasia.